New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - acarbose 100mg - tablet - 100 mg - active: acarbose 100mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose - glucobay is indicated for the additional treatment of insulin dependant and non-insulin dependant diabetes mellitus in association with diet.

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - acarbose 50mg - tablet - 50 mg - active: acarbose 50mg excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose - glucobay is indicated for the additional treatment of insulin dependant and non-insulin dependant diabetes mellitus in association with diet.

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - ciprofloxacin hydrochloride - tablet, film coated - 500 mg - ciprofloxacin hydrochloride 582.0 mg

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - ciprofloxacin lactate eqv ciprofloxacin - injection - 200 mg/100 ml - ciprofloxacin lactate eqv ciprofloxacin 200 mg/100 ml

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - ciprofloxacin hydrochloride - tablet, film coated - 250 mg - ciprofloxacin hydrochloride 291.0mg

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - acarbose - tablet - 100 mg - acarbose 100 mg

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - acarbose - tablet - 50 mg - acarbose 50 mg

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - ciprofloxacin lactate eqv ciprofloxacin - injection - 100 mg/50 ml

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn), butyl alcohol (unii: 8pj61p6ts3) (butyl alcohol - unii:8pj61p6ts3) - enrofloxacin 22.7 mg in 1 ml - baytril® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. efficacy confirmation: clinical efficacy was established in dermal infections (wounds and abscesses) associated with susceptible strains of escherichia coli , klebsiella pneumoniae , proteus mirabilis , and staphylococcus intermedius ; respiratory infections (pneumonia, tonsillitis, rhinitis) associated with susceptible strains of escherichia coli and staphylococcus aureus ; and urinary cystitis associated with susceptible strains of escherichia coli , proteus mirabilis , and staphylococcus aureus . enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in lar

United States - English - NLM (National Library of Medicine)

bayer healthcare llc animal health division - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg - baytril® (brand of enrofloxacin) antibacterial tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. baytril antibacterial tablets are indicated for use in dogs and cats. enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. dogs: based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.